Mindray Medical Provides New Product Update
07 Gennaio 2008 - 2:38PM
PR Newswire (US)
Seven New Products Launched in 2007 SHENZHEN, China, Jan. 7
/Xinhua-PRNewswire-FirstCall/ -- Mindray Medical International
Limited (NYSE:MR), a leading developer, manufacturer and marketer
of medical devices in China with a rapidly growing international
presence, today announced updates on new product launches and its
product pipeline for domestic and international markets.
'Leveraging world class R&D, Mindray provides products tailored
by both cost and functionality across markets in over 140 countries
worldwide,' said Mr. Xu Hang, Mindray's chairman and co-chief
executive officer. "It is our goal to release seven to nine
high-quality, competitively-priced products every year, which we
achieved in 2007.' Latest product launches and approvals In
November 2007, the company released the BS-120, a low-throughput
biochemistry analyzer targeted at replacing semi-automatic
bio-chemistry analyzers. It is well positioned for hospitals and
clinics in rural China as well as small hospitals and labs in
international markets. It can also serve as a backup machine for
large hospitals and labs. The BS-120 has received CE Mark and State
Food and Drug Administration ('SFDA') approval and is available in
both domestic and international markets. In December 2007, the
company released the M5, a portable diagnostic ultrasound system
for international markets. The M5 will target traditional markets
such as radiology and OB/GYN as well as Point-of-Care-Testing
('POCT') centers such as emergency and operating rooms, intensive
care units and general practice offices. The M5 is expected to be
launched in the domestic market upon SFDA approval in the first
quarter 2008. In 2007, the company released a total of seven
products including the Beneview T5 patient monitoring device, PM-60
pulse oximeter, BS-400 biochemistry analyzer, MR-96A enzyme-linked
analyzer, MW-12A microplate washer, BS-120 biochemistry analyzer
and the M5 portable diagnostic ultrasound system. The PM-7000, a
multi-parameter patient monitoring device received US Food and Drug
Administration ('FDA') 510(k) clearance in the fourth quarter 2007.
New product and approval pipeline In order to gain market share in
the high-end market segment, the company plans to release its
BC-5300 and BC-5380. Both models are compact five-part hematology
analyzers, targeted for mid-to-high-end hospitals in China and
medium-end labs in international markets. The BC-5300 and BC-5380
are expected to receive SFDA approval by the end of January 2008
and CE Mark in the first quarter 2008. The company expects its DC-3
color ultrasound diagnostic imaging system to be launched in China
and international markets upon receiving CE Mark and SFDA clearance
in the first quarter 2008. The DC-3 is designed to have wide
applications in abdominal, OB/GYN, endovaginal, cardiac, small
parts and pediatric markets. The product is suited for hospitals
and clinics seeking replacement of B/W ultrasound systems. The
company expects its EX55 and EX65 compact anesthesia machines to
receive CE Mark and SFDA approval during the first quarter 2008.
The company will apply for FDA 510(k) clearance for its Beneview
T5, T6, T8, PM-60, BS-200 chemistry analyzers and both its M5 and
DC-3 diagnostic ultrasound systems. Mindray has to date received
FDA 510(k) clearance for a total of 11 products, covering patient
monitoring devices, diagnostic laboratory instruments and
ultrasound imaging systems. About Mindray Mindray Medical
International Limited is a leading developer, manufacturer and
marketer of medical devices in China with a significant and growing
presence worldwide. Established in 1991, Mindray offers a broad
range of products across three primary business segments: patient
monitoring devices, diagnostic laboratory instruments, and
ultrasound imaging systems. Mindray is headquartered in Shenzhen,
China, and has 29 local sales and service offices in China, as well
as sales and service offices in Amsterdam, Boston, Istanbul,
London, Mexico City, Moscow, Mumbai, Sao Paulo, Seattle, Toronto
and Vancouver. For more information, please visit
http://www.mindray.com/ . Safe Harbor Statement This press release
contains "forward-looking statements" within the meaning of the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. Statements that are not historical facts, including
statements about new product releases and regulatory approvals are
forward- looking statements. Readers are cautioned that these
forward-looking statements are only predictions and may differ
materially from actual results due to a variety of factors.
Forward-looking statements involve inherent risks and
uncertainties. Information regarding these risks and uncertainties
is included in our public documents filed with the Securities and
Exchange Commission. For a discussion of some of the risks and
important factors that could affect Mindray's actual results and
financial condition, see 'Risk Factors' in Part I, Item 3D of
Mindray's Annual Report on Form 20-F for the fiscal year ended
December 31, 2006 and 'Operating and Financial Review and
Prospects' in Part I, Item 5 of Mindray's Annual Report on Form
20-F for the fiscal year ended December 31, 2006. Mindray does not
undertake any obligation to update any forward-looking statement,
except as required under applicable law. All information provided
in this press release is as of January 7, 2008, and Mindray
undertakes no duty to update such information, except as required
under applicable law. For investor and media inquiries please
contact: In China: Investor Relations Mindray Medical International
Limited Tel: +86-755-2658-2518 Email: Justin Knapp Ogilvy Public
Relations Worldwide, Beijing Tel: +86-10-8520-6556 Email: In the
United States: Jeremy Bridgman Ogilvy Public Relations Worldwide,
New York Tel: +1-212-880-5363 DATASOURCE: Mindray Medical
International Limited CONTACT: In China, Investor Relations of
Mindray Medical International Limited, +86-755-2658-2518, or , or
Justin Knapp of Ogilvy Public Relations Worldwide, Beijing,
+86-10-8520-6556, or , or in the United States, Jeremy Bridgman of
Ogilvy Public Relations Worldwide, New York, +1-212-880-5363, both
for MR Web Site: http://www.mindray.com/
Copyright
Grafico Azioni Montage Resources (NYSE:MR)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Montage Resources (NYSE:MR)
Storico
Da Lug 2023 a Lug 2024